WCA Recommendations for the Long-Term Treatment of Social Phobia
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
What is the best approach for treating patients with social phobia (social anxiety disorder) over the long term? Social phobia is the most common anxiety disorder, with reported prevalence rates of up to 18.7%. Social phobia is characterized by a marked and persistent fear of being observed or evaluated by others in social performance or interaction situations and is associated with physical, cognitive, and behavioral (ie, avoidance) symptoms. The onset of social phobia typically occurs in childhood or adolescence and the clinical course, if left untreated, is usually chronic, unremitting, and associated with significant functional impairment. Social phobia exhibits a high degree of comorbidity with other psychiatric disorders, including mood disorders, anxiety disorders, and substance abuse/dependence. Few people with social phobia seek professional help despite the existence of beneficial treatment approaches. The efficacy, tolerability, and safety of the selective serotonin reuptake inhibitors (SSRIs), evidenced in randomized clinical trials, support these agents as first-line treatment. The benzodiazepine clonazepam and certain monoamine oxidase inhibitors (representing both reversible and nonreversible inhibitors) may also be of benefit. Treatment of social phobia may need to be continued for several months to consolidate response and achieve full remission. The SSRIs have shown benefit in longterm treatment trials, while long-term treatment data from clinical studies of clonazepam are limited but support the drug's efficacy. There is also evidence for the effectiveness of exposure-based strategies of cognitive-behavioral therapy, and controlled studies suggest that the effects of treatment are generally maintained at long-term follow-up. In light of the chronicity and disability associated with social phobia, as well as the high relapse rate after short-term therapy, it is recommended that effective treatment be continued for at least 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Schneier (1992) · doi:10.1001/archpsyc.1992.01820040034004 · Cited by 1,142
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Prevalence of mental disorders and psychosocial impairments in adolescents and young adults
WITTCHEN, H.-U., NELSON, C. B., & LACHNER, G. (1998) · Psychological Medicine · doi:10.1017/s0033291797005928 · Cited by 821
WITTCHEN, H.-U., STEIN, M. B., & KESSLER, R. C. (1999) · Psychological Medicine · doi:10.1017/s0033291798008174 · Cited by 745 · cited 1×
“'(7) In epidemiological samples, there is a higher prevalence of social phobia in females than in males, but in clinical samples the gender distribution is equal, perhaps due to selection and/or recognition bias in clinical settings.(3)'(8) Rates of social phobia are consistently higher in youngerversus older-age coho…”
BackgroundCognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Mennin, D. S., Fresco, D. M., Heimberg, R. G., Schneier, F. R., Davies, S. O., & Liebowitz, M. R. (2002) · Journal of Anxiety Disorders · doi:10.1016/s0887-6185(02)00134-2 · Cited by 506
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Self-citationKESSLER, R. C., STANG, P., WITTCHEN, H.-U., STEIN, M., & WALTERS, E. E. (1999) · Psychological Medicine · doi:10.1017/s0033291799008375 · Cited by 434
Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Self-citationThe diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Goldin, P., Ramel, W., & Gross, J. (2009) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.23.3.242 · Cited by 193
Jorm, A. F., & Wright, A. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449179 · Cited by 159
Metadata
- Authors
- Van Ameringen, M., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2003-08
- Volume
- 8
- Issue
- S1
- Pages
- 40-52
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W2116311015
- Cited by
- 48
- References
- 22
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: WCA Recommendations for the Long-Term Treatment of Social Phobia. https://app.cochat.ai/papers/10.1017/s1092852900006933
- The paper
- Van Ameringen, M., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., Pollack, M. H., Stein, D. J., & Swinson, R. P. (2003). WCA Recommendations for the Long-Term Treatment of Social Phobia. CNS Spectrums. https://doi.org/10.1017/s1092852900006933
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.